Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Memorial Sloan Kettering Cancer Center MSKCC
mi
from
New York, NY
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Memorial Sloan Kettering Cancer Center MSKCC
mi
from
New York, NY
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Weill Cornell Medical College Cornell 2
mi
from
New York, NY
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Weill Cornell Medical College Cornell 2
mi
from
New York, NY
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Duke University Medical Center Duke 2
mi
from
Durham, NC
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Duke University Medical Center Duke 2
mi
from
Durham, NC
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Akron City Hospital Summa Health System Akron
mi
from
Akron, OH
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Akron City Hospital Summa Health System Akron
mi
from
Akron, OH
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital
mi
from
Columbus, OH
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Oregon Health & Science University StudyCoordinator:CBHQ880A2203
mi
from
Portland, OR
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Oregon Health & Science University StudyCoordinator:CBHQ880A2203
mi
from
Portland, OR
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
The Baylor College of Medicine/The Methodist Hospital Methodist
mi
from
Houston, TX
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
The Baylor College of Medicine/The Methodist Hospital Methodist
mi
from
Houston, TX
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
MD Anderson Cancer Center/University of Texas Univ TX MD Anderson
mi
from
Houston, TX
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
MD Anderson Cancer Center/University of Texas Univ TX MD Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3)
mi
from
San Antonio, TX
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Medical Oncology Associates PS
mi
from
Spokane, WA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Medical Oncology Associates PS
mi
from
Spokane, WA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Dean Health System Hem Onc
mi
from
Madison, WI
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Dean Health System Hem Onc
mi
from
Madison, WI
Click here to add this to my saved trials
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Status: Enrolling
Updated:  10/16/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Status: Enrolling
Updated: 10/16/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
Emory University
mi
from
Atlanta, GA
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated:  10/29/2012
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated: 10/29/2012
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated:  10/29/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated: 10/29/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Dasatinib and Cyclosporine in Patients With Chronic Myelogenous Leukemia (CML)
Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia Refractory to or Intolerant of Imatinib Mesylate (ESCAPE1b Trial)
Status: Enrolling
Updated:  10/29/2012
University of Colorado Denver
mi
from
Aurora, CO
Dasatinib and Cyclosporine in Patients With Chronic Myelogenous Leukemia (CML)
Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia Refractory to or Intolerant of Imatinib Mesylate (ESCAPE1b Trial)
Status: Enrolling
Updated: 10/29/2012
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
Phase II Study of Methotrexate, Vincristine, Pegylated L-asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
Status: Enrolling
Updated:  10/30/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
Phase II Study of Methotrexate, Vincristine, Pegylated L-asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
Status: Enrolling
Updated: 10/30/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  10/31/2012
Indiana University Cancer Center
mi
from
Indianapolis, IN
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 10/31/2012
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia
Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia, A Pilot Study
Status: Enrolling
Updated:  11/6/2012
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia
Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia, A Pilot Study
Status: Enrolling
Updated: 11/6/2012
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL
A Phase II, Single Arm Study Examining the Combination of Lenalidomide and Azacitidine (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated:  11/7/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL
A Phase II, Single Arm Study Examining the Combination of Lenalidomide and Azacitidine (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated: 11/7/2012
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  11/9/2012
Pfizer Investigational Site
mi
from
Pittsburgh, PA
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 11/9/2012
Pfizer Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated:  11/9/2012
Pfizer Investigational Site
mi
from
Bristol, TN
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
Status: Enrolling
Updated: 11/9/2012
Pfizer Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
A Phase I Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  11/12/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
A Phase I Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 11/12/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/14/2012
Loyola University
mi
from
Maywood, IL
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/14/2012
Loyola University
mi
from
Maywood, IL
Click here to add this to my saved trials
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/14/2012
SIU School of Medicine, Simmons Cancer Center
mi
from
Springfield, IL
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/14/2012
SIU School of Medicine, Simmons Cancer Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/14/2012
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/14/2012
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/14/2012
Columbia University
mi
from
New York, NY
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/14/2012
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/14/2012
Vanderbilt University
mi
from
Nashville, TN
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/14/2012
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CML, ALL, MDS, and B Cell Malignancies
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CmML, ALL, MDS, and B Cell Malignancies
Status: Enrolling
Updated:  11/15/2012
Duke Comprehensive Cancer Center
mi
from
Durham, NC
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CML, ALL, MDS, and B Cell Malignancies
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CmML, ALL, MDS, and B Cell Malignancies
Status: Enrolling
Updated: 11/15/2012
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
Birmingham, AL
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
Anaheim, CA
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
Joliet, IL
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
Joliet, IL
Click here to add this to my saved trials
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
New York, NY
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
Durham, NC
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
Klamath Falls, OR
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
Klamath Falls, OR
Click here to add this to my saved trials
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
Philadelphia, PA
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
Austin, TX
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
Kennewick, WA
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
Kennewick, WA
Click here to add this to my saved trials
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/20/2012
Bay Area Cancer Research Group
mi
from
Concord, CA
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/20/2012
Bay Area Cancer Research Group
mi
from
Concord, CA
Click here to add this to my saved trials
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/20/2012
University of Colorado Hospital
mi
from
Aurora, CO
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/20/2012
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/20/2012
SIU School of Medicine, Simmons Cancer Institute
mi
from
Springfield, IL
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/20/2012
SIU School of Medicine, Simmons Cancer Institute
mi
from
Springfield, IL
Click here to add this to my saved trials
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/20/2012
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/20/2012
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/20/2012
Columbia University
mi
from
New York, NY
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/20/2012
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/20/2012
The West Clinic, PC
mi
from
Memphis, TN
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/20/2012
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated:  11/20/2012
Vanderbilt University
mi
from
Nashville, TN
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Status: Enrolling
Updated: 11/20/2012
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials